Edwards Lifesciences (EW) insider plans Rule 144 sale of 2,615 common shares

Rhea-AI Filing Summary

Edwards Lifesciences (EW) insider plans modest Rule 144 sale of common stock. A holder intends to sell 2,615 shares of Edwards Lifesciences common stock through broker Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $218,119.00. The filing notes that approximately 580,300,000 shares of common stock were outstanding, providing context for the small size of this planned sale. The shares to be sold were acquired on 05/03/2022 through a restricted stock lapse as equity compensation from Edwards Lifesciences Corporation.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	2615	218119.00	580300000	12/12/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/03/2022	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			2615	05/03/2022	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Edwards Lifesciences (EW) Form 144 disclose in this filing?

The notice discloses an intention to sell 2,615 shares of Edwards Lifesciences common stock under Rule 144, with an aggregate market value of $218,119.00, through broker Charles Schwab & Co., Inc. on the NYSE.

How large is the planned Edwards Lifesciences (EW) share sale relative to shares outstanding?

The filing reports a planned sale of 2,615 common shares, while there were 580,300,000 shares of common stock outstanding, indicating the planned transaction is very small compared with the total.

When were the Edwards Lifesciences (EW) shares being sold originally acquired?

The shares to be sold were acquired on 05/03/2022 through a restricted stock lapse, categorized as equity compensation, from Edwards Lifesciences Corporation.

On what exchange and through which broker will the Edwards Lifesciences (EW) shares be sold?

The Form 144 states the 2,615 common shares are to be sold on the NYSE through Charles Schwab & Co., Inc., located at 3000 Schwab Way, Westlake, TX 76262.

What is the approximate date of sale for the Edwards Lifesciences (EW) Form 144 transaction?

The planned approximate date of sale for the 2,615 shares of Edwards Lifesciences common stock is listed as 12/12/2025.

What type of securities are covered by this Edwards Lifesciences (EW) Form 144?

The filing covers the planned sale of common stock of Edwards Lifesciences, acquired as equity compensation through a restricted stock lapse.